A prospective, multi center, single blind, randomized controlled study evaluating “AyurCoro3” as an adjuvant in the treatment of mild to moderate COVID
Sankhe et al.,
A prospective, multi center, single blind, randomized controlled study evaluating “AyurCoro3” as an adjuvant..,
Journal of Ayurveda and Integrated Medical Sciences, doi:10.21760/jaims.6.4.6
RCT 174 patients in India, 87 treated with AyurCoro-3 (turmeric, gomutra, potassium alum, khadisakhar, bos indicus milk, ghee), showing faster recovery with treatment. EC/NEW/INST/2019/245.
risk of death, 88.9% lower, RR 0.11, p = 0.12, treatment 0 of 87 (0.0%), control 4 of 87 (4.6%), NNT 22, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
risk of mechanical ventilation, 75.0% lower, RR 0.25, p = 0.37, treatment 1 of 87 (1.1%), control 4 of 87 (4.6%), NNT 29.
|
risk of no 2-point improvement, 46.5% lower, RR 0.54, p = 0.002, treatment 29 of 87 (33.3%), control 60 of 87 (69.0%), NNT 2.8, inverted to make RR<1 favor treatment, odds ratio converted to relative risk, day 7 mid-recovery.
|
hospitalization time, 10.0% lower, relative time 0.90, p = 0.40, treatment 87, control 87.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|

Sankhe et al., 10 Aug 2021, Randomized Controlled Trial, India, peer-reviewed, 8 authors, this trial uses multiple treatments in the treatment arm (combined with gomutra, potassium alum, khadisakhar, bos indicus milk, ghee) - results of individual treatments may vary.
Abstract: ORIGINAL ARTICLE
July-Aug 2021
A prospective, multi center, single blind, randomized
controlled study evaluating “AyurCoro3” as an adjuvant
in the treatment of mild to moderate COVID-19 patients
Ajay Prabhakar Sankhe1, Nanasaheb Somnath Memane2, Vijaykumar P. Gawali3, Sonal Nanasaheb
Memane4, Ganesh Ramakrishnan5, Mayur Nimba Bagul6, Rashmi Tiwari7, Vikram Bansal8.
1
Director, 2Head, Ayurveda Dept., 3Head, Clinical Research, 4Consultant Ayurveda, 6Research Coordinator,
Bhaktivedanta Hospital and Research Institute, Thane, Maharashtra, India. 5Professor, Computer Science and
Engineering, Indian Institute of technology, Mumbai, Maharashtra, India. 7Honorary Researcher for Pro-bona project,
Indian Institute of technology, Mumbai, Maharashtra, India. 8Research Scholar, Indian Institute of technology,
Mumbai, Maharashtra, India.
ABSTRACT
Background: There is so far no proven treatment for the unprecedented COVID-19 infections. Ayurveda holds
promise in the treatment of this viral infection. We carried out a randomized controlled trial of ‘AyurCoro-3’, a
combination of Gomutra (Bos indicus urine), hot water, turmeric, Turati Churna (potassium Alum), candy sugar
(Khadisakhar), Bos indicus milk with two teaspoons of Go Ghrut (Ghee) as an adjuvant to standard care, in
comparison to standard care alone in patients with mild-to-moderate COVID-19 infections. Methods: A
randomized, blinded, controlled trial was carried out in adult patients diagnosed with mild-to-moderate COVID-19
infections confirmed by reverse transcriptase polymerase chain reaction (RT-PCR) test. Interventional group was
administered single dose of ‘AyurCoro-3’ as an adjuvant with standard care, and the control group received only
standard of care. Validated clinical improvement scale was used for evaluating the clinical improvement, time of
resolution of presenting symptoms, duration of hospitalization, proportion of patients requiring mechanical
ventilation, and functional status scale were the key outcomes. Results: One-hundred and seventy-four patients
were recruited. Significantly more proportions of patients had resolution of all symptoms (cough, fever,
breathlessness, weakness, and tastelessness) in the interventional group compared to control. Similarly, the
interventional group also had shorter time for clinical improvement as well as shorter time of resolution for cough,
breathlessness, and weakness. No significant differences were observed in the duration of hospitalization,
proportion of patients requiring mechanical ventilation, functional status scale, and adverse events between the
groups. Conclusion: The Ayurvedic medicine ‘AyurCoro-3’ was observed to significantly shorten the duration of
COVID-19 infections and was well tolerated.
Key words: Coronavirus infections, COVID-19, Ayurveda, Complementary and Alternative Medicine
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit